摘要
目的观察尤瑞克林治疗急性进展性脑梗死的临床疗效。方法将84例急性进展性脑梗死患者随机分成对照组和治疗组,每组42例。所有患者均接受包括抗血小板聚集、调脂、控制血压及脑保护剂等基础性治疗,治疗组同时给予尤瑞克林应用,疗程为14 d。于治疗前后进行神经功能缺损程度(NIHSS)和日常生活活动能力评分(ADL),评估临床疗效。结果两组患者治疗后NIHSS评分均明显下降,治疗组下降更明显,差异有统计学意义(P<0.05)。两组患者治疗后ADL评分均明显升高,治疗组升高更明显,差异有统计学意义(P<0.05)。治疗组总有效率(88.1%)高于对照组(73.8%),差异有统计学意义(P<0.05)。结论尤瑞克林治疗急性进展性脑梗死具有确切的疗效,值得临床推广应用。
Objective To investigate the clinical effects of urinary kallidinogenase on acute progressive cerebral infarction. Methods Eighty-four patients with acute progressive cerebral infarction were selected and randomly divided into the treatment group and the control group, with 42 cases in each group. All of the patients were treated by basic therapy, including anti-platelet, lipid regulate, blood pressure control and neurologic. In addition, the patients in the treatment group were treated with urinary kallidinogenase. The degree of the national Institutes of Health Stroke Scale （NIHSS） and the activities of daily living （ADL） were evaluated before and after treatment. Results After treatment, the NIHSS scores of the patients in the two groups decreased, and the treatment group decreased more obviously, the difference was significant （P 〈 0. 05 ） ; the ADL scores of the patients in the two groups increased, and the treatment group increased more obviously, the difference was significant （P 〈 0. 05）. The total effective rate of the treatment group was higher than that of the control group, and the difference was significant （P 〈 0. 05）. Conclusions Urinary kallidinogenase has a certain clinical curative effect on acute progressive cerebral infarction, which is worthy of clinical application.
作者
刘庆杰
朱姝
Liu Qingfie;Zhu Shu(Department of Neurology, the People＇ s Hospital of Yongcheng , Yongcheng 476600, Chin)
出处
《临床医学》
CAS
2018年第5期84-86,共3页
Clinical Medicine
关键词
急性进展性脑梗死
尤瑞克林
临床疗效
Acute progressive cerebral infarction
Urinary kallidinogenase
Clinical effect
